Intramuscular Triamcinolone Acetonide Promising in Treating Acute Severe Hidradenitis Suppurativa Flares

A new study published in the Journal of Cutaneous Medicine and Surgery suggests that intramuscular triamcinolone acetonide (IMTAC) is promising in treating acute severe hidradenitis suppurativa (HS) flares.

A lack of consensus exists regarding acute flare management in HS. Intramuscular triamcinolone (IMTAC) therapy is useful in numerous inflammatory conditions; however, it has not been investigated for acute HS flares.

Study Overview

A study was done to evaluate the efficacy and patient experience associated with IMTAC therapy for acute, severe HS flares. Retrospective analysis and surveys of 45 HS patients were conducted at Albert Einstein College of Medicine/Montefiore HS Center, Bronx, NY, USA.

Results

Follow-up visits 6.77 (4.45) weeks after IMTAC therapy revealed significant reductions in:

• Mean HS-Physician Global Assessment (PGA) (P < .001)
• C-Reactive Protein (CRP) (P = .03)
• Increased hemoglobin (P = .004)
• Improved pain scores (P < .001)

Adjusting for age, sex, and concomitant medications, multivariate analysis yielded significantly reduced pain (P = .02) and increased hemoglobin (P = .03). Patient surveys indicate that IMTAC was well-tolerated, as reflected in positive mean responses for satisfaction (29 [64%]) and willingness to receive IMTAC injections again (42 [93%]).

These novel findings demonstrate that IMTAC is a safe, effective, and well-accepted adjunct for acute HS management.

Reference

Benesh G, Andriano TM, Hosgood HD, Cohen SR. Efficacy and Patient Satisfaction Associated With Intramuscular Triamcinolone Therapy for Acute Flares of Hidradenitis Suppurativa. Journal of Cutaneous Medicine and Surgery. 2023;0(0). doi:10.1177/12034754231188319

Keywords

Intramuscular, triamcinolone, acetonide, promising, treating, acute, severe, Hidradenitis, suppurativa, flares, Benesh G, Andriano TM, Hosgood HD, Cohen SR, Journal of Cutaneous Medicine and Surgery